Gregory M. Lubiniecki

32.9k total citations · 2 hit papers
56 papers, 14.3k citations indexed

About

Gregory M. Lubiniecki is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Gregory M. Lubiniecki has authored 56 papers receiving a total of 14.3k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 13 papers in Cancer Research. Recurrent topics in Gregory M. Lubiniecki's work include Cancer Immunotherapy and Biomarkers (43 papers), Lung Cancer Treatments and Mutations (23 papers) and Cancer Genomics and Diagnostics (13 papers). Gregory M. Lubiniecki is often cited by papers focused on Cancer Immunotherapy and Biomarkers (43 papers), Lung Cancer Treatments and Mutations (23 papers) and Cancer Genomics and Diagnostics (13 papers). Gregory M. Lubiniecki collaborates with scholars based in United States, Spain and South Korea. Gregory M. Lubiniecki's co-authors include Yue Shentu, Rina Hui, Reshma Rangwala, Delvys Rodríguez‐Abreu, Andrew Robinson, Tibor Csőszi, Ali Tafreshi, Mary O’Brien, Nir Peled and Suman Rao and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Gregory M. Lubiniecki

55 papers receiving 14.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

2016 7.1k citations Martin Reck, Delvys Rodríguez‐Abreu et al. profile →
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

2015 4.9k citations Roy S. Herbst, Paul Baas et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gregory M. Lubiniecki United States	25	12.2k	8.1k	2.9k	1.8k	1.4k	56	14.3k
Yue Shentu United States	15	10.7k 0.9×	7.0k 0.9×	2.5k 0.9×	1.5k 0.8×	1.3k 0.9×	34	12.6k
Katsuyuki Hotta Japan	40	11.2k 0.9×	8.7k 1.1×	2.0k 0.7×	1.7k 1.0×	2.1k 1.5×	288	14.1k
Maya Gottfried Israel	33	10.7k 0.9×	7.7k 1.0×	2.0k 0.7×	1.7k 1.0×	1.9k 1.4×	156	13.3k
Delvys Rodríguez‐Abreu Spain	38	15.1k 1.2×	10.1k 1.2×	3.5k 1.2×	2.0k 1.1×	2.0k 1.4×	186	18.0k
Tibor Csőszi United States	22	9.1k 0.7×	5.8k 0.7×	1.9k 0.7×	1.3k 0.7×	1.3k 0.9×	82	10.7k
Marisa Dolled‐Filhart United States	34	8.1k 0.7×	4.8k 0.6×	1.9k 0.7×	1.8k 1.0×	2.4k 1.7×	69	11.3k
Valerie S. Barta United States	5	9.6k 0.8×	3.7k 0.5×	4.2k 1.5×	1.1k 0.6×	2.0k 1.4×	6	11.7k
Suman Rao United States	10	7.9k 0.6×	5.4k 0.7×	1.8k 0.6×	1.2k 0.6×	895 0.6×	21	9.3k
Andrea Fülöp Hungary	9	7.9k 0.6×	5.3k 0.7×	1.8k 0.6×	1.2k 0.6×	898 0.6×	14	9.2k
Reshma Rangwala United States	18	7.0k 0.6×	4.4k 0.5×	1.8k 0.6×	1.2k 0.6×	1.4k 1.0×	41	9.2k

Countries citing papers authored by Gregory M. Lubiniecki

Since Specialization

Citations

This map shows the geographic impact of Gregory M. Lubiniecki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory M. Lubiniecki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory M. Lubiniecki more than expected).

Fields of papers citing papers by Gregory M. Lubiniecki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory M. Lubiniecki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory M. Lubiniecki. The network helps show where Gregory M. Lubiniecki may publish in the future.

Co-authorship network of co-authors of Gregory M. Lubiniecki

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory M. Lubiniecki. A scholar is included among the top collaborators of Gregory M. Lubiniecki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory M. Lubiniecki. Gregory M. Lubiniecki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Herbst, Roy S., Edward B. Garon, Dong‐Wan Kim, et al.. (2020). Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study. Journal of Clinical Oncology. 38(14). 1580–1590. 201 indexed citations

Garassino, Marina Chiara, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel, et al.. (2019). OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC. Journal of Thoracic Oncology. 14(10). S216–S217. 66 indexed citations

Halmos, Balázs, Alexander Luft, Margarita Majem, et al.. (2018). MA10.08 Choice of Taxane and Outcomes in the KEYNOTE-407 Study of Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC. Journal of Thoracic Oncology. 13(10). S391–S391. 4 indexed citations

Lopes, Gilberto, Yi‐Long Wu, Iveta Kudaba, et al.. (2018). Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.. Journal of Clinical Oncology. 36(18_suppl). LBA4–LBA4. 138 indexed citations

Herbst, Roy S., Edward B. Garon, D.-W. Kim, et al.. (2018). Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro). Annals of Oncology. 29. viii749–viii749. 17 indexed citations

Brahmer, Julie R., Delvys Rodríguez‐Abreu, Andrew Robinson, et al.. (2017). PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024. Journal of Thoracic Oncology. 12(1). S8–S9. 10 indexed citations

Hui, Rina, Edward B. Garon, Natasha B. Leighl, et al.. (2017). Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Annals of Oncology. 28(4). 874–881. 188 indexed citations

Dolled‐Filhart, Marisa, Charlotte Roach, Grant Toland, et al.. (2016). Development of a Companion Diagnostic for Pembrolizumab in Non–Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1. Archives of Pathology & Laboratory Medicine. 140(11). 1243–1249. 86 indexed citations

Barlési, Fabrice, Edward B. Garon, Dongwook Kim, et al.. (2016). Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC. Annals of Oncology. 27. vi422–vi422. 9 indexed citations

10.

Herbst, Roy S., Paul Baas, Dongwook Kim, et al.. (2016). Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010. Annals of Oncology. 27. vi583–vi583. 6 indexed citations

11.

Lee, J.-S., et al.. (2015). 461P Patients (Pts) with advanced NSCLC from Korea treated with pembrolizumab (Pembro) in KEYNOTE-001. Annals of Oncology. 26. ix125–ix125.

12.

Ahn, Myung‐Ju, Leena Gandhi, Omid Hamid, et al.. (2015). 459P Risk of pneumonitis in patients with advanced NSCLC treated with pembrolizumab in KEYNOTE-001. Annals of Oncology. 26. ix125–ix125. 15 indexed citations

13.

Herbst, Roy S., Paul Baas, Dong‐Wan Kim, et al.. (2015). Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet. 387(10027). 1540–1550. 4873 indexed citations breakdown →

14.

Dolled‐Filhart, Marisa, et al.. (2015). Development of a PD-L1 immunohistochemistry (IHC) assay for use as a companion diagnostic for pembrolizumab (MK-3475) in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 33(15_suppl). 11065–11065. 8 indexed citations

15.

Herbst, Roy S., D.-W. Kim, Enriqueta Felip, et al.. (2015). LBA3_PR KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1–positive NSCLC after platinum-based therapy. Annals of Oncology. 26. ix161–ix161. 1 indexed citations

16.

Krug, Lee M., Hedy L. Kindler, Hilary Calvert, et al.. (2015). Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. The Lancet Oncology. 16(4). 447–456. 143 indexed citations

17.

Garon, Edward B., Leena Gandhi, Naiyer A. Rizvi, et al.. (2014). Antitumor Activity of Pembrolizumab (Pembro; Mk-3475) and Correlation with Programmed Death Ligand 1 (Pd-L1) Expression in a Pooled Analysis of Patients (Pts) with Advanced Non–Small Cell Lung Carcinoma (Nsclc). Annals of Oncology. 25. v1–v1. 53 indexed citations

18.

Kirschbaum, Mark, Ivana Gojo, Stuart L. Goldberg, et al.. (2014). A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. British Journal of Haematology. 167(2). 185–193. 96 indexed citations

19.

Vaughn, David J., Gregory M. Lubiniecki, & S. Bruce Malkowicz. (2005). Neoadjuvant Chemotherapy in Bladder Cancer. 4(2). 71–75. 1 indexed citations

20.

O’Reilly, Séamus, Sharyn D. Baker, S E Sartorius, et al.. (1998). A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion. Annals of Oncology. 9(1). 101–104. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact